Article Reference Code: NAMAS.10.30.2026
Written By: Natasha Timberlake, MSHIM, CPC, COC, CPMA, CHONC, CPC-I, CEMA
I’ve worked in Oncology/Hematology for over 4 years now, and it is by far my favorite specialty. It is also the first service line that I learned to code. I started out coding infusions and injections, then learned E/M, and now I’m in provider education and compliance in Oncology. It can be a difficult, intricate specialty to learn, but it can also be rewarding, especially because of the patient care and passion it brings.
What I didn’t anticipate, and most of us don’t, is being on the other side of the field as a patient. I was diagnosed with breast cancer right before Thanksgiving last year. Working in the field already helped me understand and compartmentalize everything. Still, it also had a flip side: I knew too much and overanalyzed everything because of how things could turn out.
I had a mammogram that unfortunately had suspicious breast calcifications that needed further review. I had a biopsy, and it confirmed breast cancer. Unfortunately, it isn’t that simple. We had to wait for the pathology report and tumor markers. Beyond confirming a malignant neoplasm, tumor markers are an important part of the treatment plan because they help the physician determine the stage, grade, Ki-67 Proliferative Index, and receptor status. For instance, the difference between ER+ (Estrogen Receptor) and ER– (Estrogen Receptor) can significantly affect the overall treatment plan. We also need to take into account the Progesterone receptors and HER2 (Human Epidermal Growth Factor) receptors and whether they are also (+) or (-). What we code is the confirmed breast cancer diagnosis and the tumor markers. We don’t code stages, grades, or Ki-67 levels, but they still matter for the patient’s treatment. They can help initiate consults with other specialties, such as Surgical Oncology, Radiation Oncology, and Plastic Surgery.
For me, I have a malignant neoplasm of the lower outer quadrant of the right breast, and I am triple-negative. That means that all of my tumor markers were negative. My stage was 2 (around 2 cm in size), which is the size of my cancer, and my grade was 3, which means that it was aggressive. My Ki-67 Proliferative Index was 91-100%. This also showed and confirmed how fast the tumor was growing. Even though we don’t code these, reviewing my pathology report and tumor markers helps me better understand what’s going on. In my opinion, we should add codes for stages and grades to support statistical analysis, especially for different cancer types that use them.
Because I am triple negative, my cancer doesn’t react to hormones, so my treatment plan will be different than someone who has a hormone-positive type of breast cancer. Understanding this is essential not only for coding, but also for documentation and the patient’s specific treatment. For instance, I had to have 6 months of neoadjuvant chemotherapy and immunotherapy before I was able to have surgery. Chemotherapy and immunotherapy are coded the same based on the documentation, whether it is
neoadjuvant or adjuvant. The difference between neoadjuvant and adjuvant is that neoadjuvant is before surgery and adjuvant is after surgery. Another person who has a positive receptor may not need chemotherapy, or if they do, it would be after surgery. But that person may need hormone blockers, and the cancer may not be receptive to chemotherapy, which is why it isn’t needed.
Each diagnosis and treatment plan is individualized, and consultations with different providers may be needed depending on the circumstances. I had a consultation with Radiation Oncology, and if chemotherapy and surgery were successful, then I wouldn’t need radiation. I also met with Breast Surgery and Plastic Surgery, and we decided to have a double mastectomy with a DIEP Flap reconstruction for my surgery. DIEP stands for deep inferior epigastric perforator. I completed my chemotherapy in June of this year, and my surgery was completed in July. I didn’t realize how extensive this type of surgery would be, and that Breast Surgery and Plastic Surgery normally work hand in hand on these types of procedures. Chemotherapy was successful in reducing the size of my cancer, and my double mastectomy was successful in removing the remaining cancer.
Unfortunately, I had a complication from the first surgery with the DIEP Flap transfer to my right breast, and my right side failed. I had another surgery in October performed by Plastic Surgery only, but now the flap was from my inner thighs to replace my right breast. It is called TUG — Transverse Upper Gracilis. I honestly had never heard of my second surgery until it became an option. The DIEP Flap is a normal option for reconstruction surgery if using your own body for reconstruction. I had no idea these surgeries included Plastic Surgeons who specialize in microsurgery on arteries and veins.
There is also an option to have a lumpectomy, single mastectomy, expanders to implants, or to go flat. Each surgery is specific to the patient, and it is a hard decision to make with the care team, even with all of the information provided. Depending on what type of surgery you have, you may have additional treatment, such as a lumpectomy with radiation afterward. Or the person may have an option where surgery isn’t needed or, unfortunately, isn’t an option.
I share my story not to advise you to use your experiences or personal history to infer while reviewing the documentation in whichever specialty you are in, but to share knowledge and use your experiences and personal history to dig deeper and understand the “why” behind it all. Even if there isn’t a code for it, understanding the “why” behind the treatment helps explain why certain specialties document treatments, procedures, and patient visits a certain way, and what it all entails. I encourage all of you to dig deeper in your specialty, learn what else you can, and explore how other specialties may work together.

Connect with Natasha on LinkedIn by Clicking her Name Below:
Natasha Timberlake, MSHIM, CPC, COC, CPMA, CHONC, CPC-I, CEMA
NAMAS BLOG Disclaimer:
The NAMAS Blog features content written by both NAMAS staff and guest contributors. Guest contributors may present opinions or perspectives that differ from those officially instructed or encouraged by NAMAS. We believe in providing space for a range of informed viewpoints to foster dialogue, reflection, and deeper understanding within the auditing and compliance community.
Some contributors may use artificial intelligence (AI) tools in the development of their content. The decision to incorporate AI is left to the discretion of the author and does not reflect an endorsement or directive from NAMAS.
If you have questions, comments, or concerns about a specific blog post, we encourage you to contact the individual author directly. Their name and contact information are provided at the end of each post.












